XOMA. Bull or Bear? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear?

XOMA 25.54

+1.4%

3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Cacaito who wrote (15912)	7/22/2002 12:31:44 AM
From: Cacaito	of 17367

from xoma pr circa 1998: "for use in the RECENTLY approved Rituxan(tm) product. "This innovative transaction adds another product to our portfolio while enabling XOMA to realize significant cash to fund its core development programs," said Dave Madden of Pharmaceutical Partners. His partner Pablo Legorreta added, "Pharmaceutical Partners was created to invest in royalty interests in pharmaceutical products, and as in the XOMA transaction, we are providing non-recourse, non-dilutive financing in exchange for assuming the risk of the royalty stream on a specific product." "An important part of our business strategy has been to realize value from our non-core technologies to fund development of our BPI product platform," said some chairman, president and CEO of XOMA. "This transaction is a good example of the benefits that can come from this approach." Elan was called idiot and/or dishonest for a phase I to II product deal, that they could recovered the % in deal. The ones who gave 2% of an already FDA approved one were financial geniuses! Dna fought everyone for 1%, they are morons, they should have follow the 1% sellers to "Pharmaceutical Partners". Yes, drop the chalupa !!!

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next